Nadolol Neon Healthcare (Nadolol)

Nadolol blocks both β1 and β2 adrenergic receptors, preventing catecholamines such as adrenaline from stimulating the heart and blood vessels. This inhibition reduces heart rate, myocardial contractile force, and renin release, leading to lower cardiac output and systemic vascular resistance, which together lower blood pressure and decrease myocardial oxygen demand.

The specific dose of Nadolol is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any comorbidities. Dosage may be adjusted over time, and patients should follow the exact regimen provided by their healthcare professional.

Safety data for nadolol in pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile before prescribing it to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nadolol is a non‑selective beta‑blocker, meaning it blocks both β1 and β2 receptors, whereas some alternatives such as atenolol are β1‑selective. This broader blockade can be advantageous for hypertension but may increase the risk of bronchospasm in patients with reactive airway disease. Its long half‑life often allows once‑daily dosing, which can improve adherence compared with shorter‑acting agents.

Nadolol should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Nadolol is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to maintain consistent absorption and therapeutic effect.

Serious adverse events include markedly low heart rate (bradycardia), dangerously low blood pressure (hypotension), bronchospasm especially in patients with asthma or COPD, and severe allergic reactions such as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like fainting, severe shortness of breath, or swelling of the face and throat.

Nadolol is contraindicated in individuals with severe bradycardia, second‑ or third‑degree heart block, uncompensated heart failure, severe asthma or chronic obstructive pulmonary disease, and in patients with known hypersensitivity to nadolol or any component of the formulation. Clinicians must evaluate each patient’s medical history before initiating therapy.